ELVN vs PFE
ELVN: Enliven Therapeutics is a precision oncology company developing next-generation small molecule inhibitors, led by its clinical-stage BCR-ABL program for chronic myeloid leukemia. PFE: A diversified, global biopharmaceutical giant focused on discovering and commercializing life-changing medicines, vaccines, and advanced therapies across key therapeutic areas.
Side-by-side fundamentals
| Metric | ELVN | PFE | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $59.82 | $28.07 | |
| Market cap as of 2026-08-24 | $4.4B | $160.0B | |
| P/E as of 2026-08-24 | n/a | 35.19 | |
| PEG as of 2026-08-24 | n/a | -2.72 | |
| Net margin as of 2026-08-24 | n/a | +6.8% | |
| Gross margin as of 2026-08-24 | n/a | +74.7% | |
| Operating margin as of 2026-08-24 | n/a | +6.8% | |
| ROE as of 2026-08-24 | -18.6% | +4.9% | PFE higher |
| ROA as of 2026-08-24 | -18.1% | +2.1% | PFE higher |
| Debt / equity as of 2026-08-24 | 0.00 | 0.74 | ELVN lower |
| Revenue growth (YoY) as of 2026-08-24 | n/a | -0.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -14.8% | |
| Dividend yield as of 2026-08-24 | n/a | +5.4% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-24 | 0.46 | 0.28 | |
| 1-year return as of 2026-08-21 close | +201.5% | +9.1% | ELVN higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.